Clinically Actionable Insights into Initial and Matched Recurrent Glioblastomas to Inform Novel Treatment Approaches

Table 1

Summary of the clinical data for patients genomically profiled in this study (n = 41). Patients with IDH-wildtype and IDH-mutant glioblastoma tumours were identified from the BRASH clinical database between 2009 and 2014.

Characteristic	IDH-wildtype	IDH-mutant
Number of patients	38	3
Age
Mean	54	42
Median (range)	52 (16–78)	50 (19–58)
Gender
Male	19 (50%)	2 (66%)
Female	20 (50%)	1 (33%)
Survival range (months)	2–48	5–12
Tumour location
Temporal lobe	8 (21%)	2 (66%)
Frontal lobe	15 (39%)
Parietal lobe	4 (11%)
Occipital	4 (11%)
More than one lobe	5 (13%)	1 (33%)
Multifocal	1 (3%)
No data	1 (3%)
Tumour recurrence
Initial	38	3
Recurrent	7	1